Novartis Institute for Tropical Diseases chooses Genedata Software Solutions

30.06.2005, Novartis Institute for Tropical Diseases chooses Genedata Software Solution for anti-infectives Research.

Genedata AG today announced a collaboration with Novartis Institute for Tropical Diseases (NITD) in Singapore involving the Genedata Phylosopher PathoLead edition to advance research in progressive infectious and parasitic disease. Genedata Phylosopher(R) will serve as an organization-wide scientific management system for proprietary data integration.

Scientists at NITD will use the software to identify and validate target candidates and to prioritize development of novel drug classes. Research at NITD focuses on Dengue fever and tuberculosis, the two most life-threatening tropical diseases. There’s no treatment for Dengue and trends suggest an epidemic could extend beyond the Developing world. The ultimate goal would be to develop an anti-viral treatment. Tuberculosis is commonly perceived to be well controlled, but more people die of it today than at any other time in history. There are no alternative treatments and no new drugs have come to market for 30 years.

Genedata Phylosopher will enable scientists at the NITD to reconstruct pathways and perform comparative genomic analysis of complex host-pathogen interactions such as human-animal infection models. By integrating experimental data from genomic, transcriptomic, proteomic and metabolomic sources with knock-out data and other results, they will explore mechanisms underlying infection and treatment-action at the molecular level. Such sophisticated analyses are essential for identifying novel targets, generating screening assays, and developing effective therapies.

Genedata’s collaborations now span oncology, CNS, metabolic diseases, predictive toxicology and biomarker discovery.

More information can be found under www.genedata.com

Hinweis der Redaktion: Die Bildrechte liegen beim jeweiligen Herausgeber.

Über Novartis Pharma Schweiz AG:

Die Novartis Pharma Schweiz AG ist eine Tochtergesellschaft der Novartis Pharma AG Basel. Als eines der grössten Schweizer Pharma-Unternehmen sind wir in der Schweiz für die verschreibungspflichtigen Medikamente von Novartis verantwortlich.

Die rund 220 Mitarbeiterinnen und Mitarbeiter sind in den Bereichen des Marketings und des Vertriebs beschäftigt, beraten im Aussendienst niedergelassene Aerzte und Spital-Aerzte oder betreuen Projekte in der klinischen Forschung, der wissenschaftlichen Dokumentation und der Registrierung von neuen Medikamenten.

Hinweis: Der Über-uns-Text stammt aus öffentlichen Quellen oder aus dem Firmenporträt auf HELP.ch.

--- Ende Artikel / Pressemitteilung Novartis Institute for Tropical Diseases chooses Genedata Software Solutions ---


Weitere Informationen und Links:

	Novartis Pharma Schweiz AG (Firmenporträt)
	Artikel 'Novartis Institute for Tropical Diseases chooses Genedata Software Solutions...' auf Swiss-Press.com